Big 2017 Change on PSA by USPSTF

Marc B Garnick, MD, Editor in Chief, HMS Annual Report on Prostate Diseases; Gorman Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA E. David Crawford, MD, Professor of Urology and Radiation Oncology at The University of Colorado, Anschutz Campus, Aurora, CO; Medical Advisor and Founder, 3DBiopsy, Inc., Aurora, CO […]

Forget Moonshots: Biomedicine Needs an Air Traffic Control System

Jeff Shrager, PhD, Director of Research, Cancer Commons; Adjunct Professor, Symbolic Systems Program, Stanford University Q: There never seem to be enough patients matched to cancer clinical trials to quickly test new cancer treatments. Might there be a better way, using new communication technology? A: Among the few things that everyone can agree upon, one […]

Proposed FDA “Conditional Approval”- More Details

Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Follow Al Follow Marty Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. […]

Next Steps for Improving Clinical Evidence and Consistency of Payment for Precision Oncology

Kathryn A. Phillips, PhD, Professor of Health Economics and Health Services Research; Founding Director UCSF Center for Translational and Policy Research on Personalized Medicine; Dept. of Clinical Pharmacy; Institute for Health Policy Studies; Comprehensive Cancer Center University of California, San Francisco Q: Adoption and insurer coverage for precision oncology may require evidence that it can […]

Conditional Approval: Right Solution for the Wrong Problem

Shannon Brownlee, MS, Senior Vice President of the Lown Institute, a think tank in Boston. She is also co-founder of the Right Care Alliance, a social movement for transforming health care. Q: Musella and Tenenbaum recently proposed a new way, called conditional approval, for the American FDA to move potentially useful drugs to a patient […]

In Memorium: Richard E. Horowitz, M.D.

by Dr. George Lundberg Searching for Truth in Cancer Clinical Trials Richard E. Horowitz, MD, Clinical Professor of Pathology, Keck School of Medicine at USC; Emeritus Professor of Pathology, UCLA School of Medicine; Consulting Pathologist, Los Angeles Veteran’s Affairs Medical Center Q: Who has been among the strongest supporters and most constructive critics of CollabRx […]

Fibrolamellar Hepatocellular Carcinoma: Still Rare but Deadly

John R. Craig, MD PhD, Retired pathologist and formerly Medical Director, St. Jude Cancer Center, Fullerton, CA; Member, Board of Directors, FibroFoundation Q: You were the lead author in a 1980 paper in Cancer that clearly delineated an unusual form of Hepatocellular Carcinoma that you termed “Fibrolamellar Carcinoma”. Now, 37 years later, what insights of […]

A Proposed New FDA Drug Approval Pathway: “Conditional”

Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Follow Al Follow Marty Q: The delay time from discovery/observation, through validation to approval and distribution/use of new cancer treatments remains excessive. With promising experimental treatments, advanced computer technology […]

AACR: Advances in Immunotherapy to Continue

Srivani Ravoori, PhD, Associate Director, Science Communications; American Association for Cancer Research Intro: The American Association for Cancer Research (AACR) publishes a forecast blog post at the start of each year to ask┬áprominent cancer research leaders what they envision the new developments will be in areas like immunotherapy, precision medicine, cancer prevention, and health disparities. […]

A Fully Integrated Histo-Molecular Pathology Report

Margaret L. Gulley, MD, Professor of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill Q: The CAP, ASCO, ASCP and AMP have developed guidelines for interpretation and reporting of NGS variants in cancers. These analyses are performed in a wide range of types of labs and involve professionals from many disciplines. The […]